As of November 14, 2026, Avidity Biosciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 27, 2026 (Form 8-K, February 27, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Avidity Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Avidity Biosciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-27. Every row below is cited to the filing it comes from, and this page adds each new change as Avidity Biosciences, Inc. files it.
Also on the record for Avidity Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Avoro Capital Advisors LLC | 5.54% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 4.6% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 0.1% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 0.5% of the class | 5%+ stakes | Source |
| December 5, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 5.5% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 10.7% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 5.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 7.1% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 2.1% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 9.57% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Avidity Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Avidity Biosciences, Inc. and the records around it.
Avidity Biosciences, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Who owns it
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: ORCHESTRA BIOMED HOLDINGS, INC. (Nov 2026), CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Evommune, Inc. (Nov 2026), Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026)
Watch Avidity Biosciences, Inc.
Get an email when Avidity Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Avidity Biosciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Avidity Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avidity Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-27 | Reported | not named in the filing | 8-K, 2026-02-27 |
New leaders reset buying decisions — get the Full Report on Avidity Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Avidity Biosciences, Inc., with the record behind each one.
Find candidates like senior executive at Avidity Biosciences, Inc.Every change, in the filing's words
Reported
In connection with the consummation of the Merger and as contemplated by the Merger Agreement, as of the Effective Time, each of the directors of the Company (Carsten Boess, Sarah Boyce, Troy Wilson, Ph.D., J.D., Arthur A. Levin, Ph.D., Simona Skerjanec, Tamar Thompson, Noreen Henig, M.D., Edward M. Kaye, M.D. and Jean Kim) resigned and ceased to be directors of the Company and members of any committee of the Company's board of directors.
- These resignations were not a result of any disagreement between the Company and the directors on any matter relating to the Company's operations, policies or practices.
- In connection with the consummation of the Merger and as contemplated by the Merger Agreement, as of the Effective Time, the directors of Merger Sub immediately prior to the Effective Time became the directors of the Surviving Corporation.
- The directors of Merger Sub immediately prior to the Effective Time were Jaime Huertas and Eduard Marti.
- In connection with the consummation of the Merger and as contemplated by the Merger Agreement, as of the Effective Time, all executive officers of the Company immediately prior to the Effective Time (Sarah Boyce, Charles Calderaro III, W. Michael Flanagan, Ph.D., Katleen Gallagher, Steven Hughes, M.D., Michael F. MacLean, Teresa McCarthy, John B. Moriarty, Jr, J.D. and Eric Mosbrooker) were removed from their respective positions as the executive officers of the Surviving Corporation.
- In connection with the consummation of the Merger and as contemplated by the Merger Agreement, as of the Effective Time, the executive officers of Merger Sub immediately prior to the Effective Time became the executive officers of the Surviving Corporation.
Tools for this story
Each opens in a new tab, filled in for Avidity Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
